
Children receiving 50 nmol PVX108 increased their tolerated peanut dose 2.4-fold, with no treatment-related anaphylaxis in the phase 2 trial.
In this MEDcast episode, Raj Chovatiya, MD, PhD, and George Han, MD, PhD, interview Brett King, MD, PhD, to discuss the latest advances in the treatment of alopecia areata.






